Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
14 mrt 2016 - 07:02
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma Satellite Symposium at 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation
Bericht
Amsterdam, The Netherlands, March 14, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it will organise a satellite symposium on April 3, 2016 at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
The satellite symposium is entitled: “Prevention and treatment of relapses after haploidentical HSCT: An ideal opportunity for cell-based therapy?” and will be chaired by Dr. Stefan Ciurea, Associate Professor at the University of Texas MD Anderson Cancer Center, Houston, USA. The symposium will address the issue of relapse following (haploidentical) stem cell transplantations and the opportunities for donor lymphocyte infusion post-transplantation, and will discuss current knowledge on other cell-based approaches such as NK-cell and CAR-T cell therapies.
The speakers are international key opinion leaders in the field of hematopoietic stem cell transplantation: Prof. Arnon Nagler (Chaim Sheba Medical Center, Tel-Hashomer, Israel), Prof. Andrea Bacigalupo (Università Cattolica Policlinico Gemelli, Rome, Italy) and Prof. Dr. Stephan Mielke (Universitätsklinikum Würzburg, Würzburg, Germany).
The satellite symposium will take place in the industry sponsored and supported program on Sunday April 3, 2016 from 11.00 – 12.30 CET in Room 3F-3G of the EBMT conference venue.
Datum laatste update: 29 juli 2024